1E Therapeutics
Novel RNA-targeting Drugs
Startup1E Therapeutics is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2021. Novel RNA-targeting Drugs. The company has raised a total of $120M across 1 funding round, currently at the Seed stage. Key investors include Marius Nacht. The company has 11-50 employees. Core technologies: Biologicals, Molecules.
With $120M in total funding, 1E Therapeutics is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQRehovot
- DistrictCenter District
- Last Round$120M
- Marius NachtLead
1 article covered by sources including www.calcalistech.com.
What does 1E Therapeutics do?
1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform. 1E's process has proven able to develop drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.
How much funding has 1E Therapeutics raised?
1E Therapeutics has raised $120M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Marius Nacht.
What sector is 1E Therapeutics in?
1E Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is 1E Therapeutics located?
1E Therapeutics is based in Haim Holtsman Street 7, Rehovot, Israel, Center District.